Featured Articles

  1. A 250 Million Patient Blind Spot: Why Pharma Ignored Lymphatic Medicine 10/21/2026

    Once overlooked as the merely the human body’s plumbing, the lymphatic system is emerging as a new therapeutic frontier, writes Celltaxis CEO Eileen Heffernan.

  2. The Bond Factor: Resilience Through Change 10/15/2026

    In her third and final installment of the Bond Factor leadership series, Wanda Shoer offers advice for navigating work and professional changes effectively.

  3. The Future Of Life Sciences Supply Chain Distribution 10/13/2026

    Life sciences distribution is shifting toward AI-powered, resilient networks that improve speed, efficiency, compliance, and patient care, according to experts at EY. 

  4. Stop Planning For The Year You Think You're Going To Have 10/9/2026

    Life sciences leaders should plan for multiple futures and adapt their strategies as new evidence arrives, writes Jason C. Bork. 

  5. What Thirty Years Of EBVST Teaches Us About Off-The-Shelf Cell Therapy 10/7/2026

    After 30 years of use in transplant medicine, EBV-specific T cells offer key lessons for safer, scalable allogeneic cell therapies, writes Ivan Horak, M.D.

  6. The Case For Reciprocal Due Diligence In Life Sciences Board Recruitment 10/1/2026

    Candidates for seats on company boards should scrutinize governance, culture, and leadership dynamics before saying yes, writes DeeDee DeMan.

  7. Targeting p27 To 'Let Biology Do The Work' With Stacy Blain, CEO, Concarlo Therapeutics 9/29/2026

    Stacy Blain, PhD, turned 30 years of p27 research into Concarlo’s LOCKTAC, a molecular glue designed to restore natural CDK2/4/6 inhibition in cancer.

  8. The Strength Behind Servant Leadership 9/28/2026

    Servant leadership means putting people first because results follow people, not the other way around, writes Boehringer Ingelheim’s Christine Sakdalan.

  9. How To Choose A Contract Sales Organization For A 2027 Launch 9/22/2026

    Five of the best-known contract sales providers have changed owners, leaders, or reporting structure since 2022. Contracts should reflect those changes, writes Hoyt Gong.

  10. Wall Street Is Wary Of NAMs — And For Good Reason: What Happens To Yesterday's Drugs? 9/15/2026

    Part 2 follows the consequences into Wall Street, asking what better evidence could mean for pharmaceutical valuations and, ultimately, drugs already in the portfolio.